Jordan
Tuberculosis profile
Population  2012 7 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.037 (0–0.42) 0.53 (0–6)
Mortality (HIV+TB only) 0 (0–7 000) 0 (0–100 000)
Prevalence  (includes HIV+TB) 0.6 (0.28–1) 8.5 (3.9–15)
Incidence  (includes HIV+TB) 0.4 (0.36–0.46) 5.8 (5.1–6.5)
Incidence (HIV+TB only) <0.01 (0–<0.01) 0 (0–0)
Case detection, all forms (%) 82 (72–93)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 85 (26) Relapse 1 (5)
Smear-negative 69 (21) Treatment after failure 0 (0)
Smear-unknown / not done 4 (1) Treatment after default 0 (0)
Extrapulmonary 172 (52) Other 18 (95)
Other 0 (0)      
Total new 330   Total retreatment 19  
           
Other (history unknown) 0        
Total new and relapse 331   Total cases notified 349  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.2 1.0 0.5
Age < 15 1 5 29
Laboratories 2012
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 92   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 89  
Retreatment 80  
TB/HIV 2012 Number (%)
TB patients with known HIV status 177 (51)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 6.3 (2.4–13) 29 (3.7–71)
MDR-TB cases among notified pulmonary
TB cases
10 (4–21) 5 (1–13)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 77 (91%) 6 (32%) 85
Laboratory-confirmed MDR-TB cases 8 3 13
Patients started on MDR-TB treatment     16
Financing TB control 2013
National TB programme budget (US$ millions) 2.6
% Funded domestically 63%
% Funded internationally 23%
% Unfunded 14%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-18 Data: www.who.int/tb/data